Complex fibroadenoma and breast cancer risk: a Mayo Clinic Benign Breast Disease Cohort Study

• Published in: Breast cancer research and treatment Vol. 153; no. 2; pp. 397 - 405
• Main Authors: Nassar, Aziza, Visscher, Daniel W., Degnim, Amy C., Frank, Ryan D., Vierkant, Robert A., Frost, Marlene, Radisky, Derek C., Vachon, Celine M., Kraft, Ruth A., Hartmann, Lynn C., Ghosh, Karthik
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.09.2015; Springer; Springer Nature B.V
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Biopsy; Breast cancer; Breast Neoplasms - epidemiology; Breast Neoplasms - etiology; Cancer research; Clinical trials; Cohort Studies; Comparative analysis; Epidemiology; Female; Fibroadenoma - complications; Fibroadenoma - diagnosis; Fibrocystic Breast Disease - complications; Fibrocystic Breast Disease - diagnosis; Follow-Up Studies; Health aspects; Health risk assessment; Humans; Mammography; Medicine; Medicine & Public Health; Middle Aged; Oncology; Risk; Risk factors; Tumors; Women; Young Adult; Breast cancer; Mayo Clinic benign breast disease cohort; Fibroadenoma; Benign breast disease; Cancer risk
• ISSN: 0167-6806; 1573-7217
• DOI: 10.1007/s10549-015-3535-8

The purpose of this study is to examine the breast cancer risk overall among women with simple fibroadenoma or complex fibroadenoma and to examine the association of complex fibroadenoma with breast cancer through stratification of other breast cancer risks. The study included women aged 18–85 years from the Mayo Clinic Benign Breast Disease Cohort who underwent excisional breast biopsy from 1967 through 1991. Within this cohort, women who had fibroadenoma were compared to women who did not have fibroadenoma. Breast cancer risk (observed versus expected) across fibroadenoma levels was assessed through standardized incidence ratios (SIRs) by using age- and calendar-stratified incidence rates from the Iowa Surveillance, Epidemiology, and End Results registry. Analyses were performed overall, within subgroups of involution status, with other demographic characteristics (age, year of biopsy, indication for biopsy, and family history), and with histologic characteristics, including overall impression [nonproliferative disease, proliferative disease without atypia (PDWA), or atypical hyperplasia]. Fibroadenoma was identified in 2136 women [noncomplex, 1835 (85.9 %); complex, 301 (14.1 %)]. SIR for noncomplex fibroadenoma was 1.49 (95 % CI 1.26–1.74); for complex fibroadenoma, it was 2.27 (95 % CI 1.63–3.10) (test for heterogeneity in SIR, P  = .02). However, women with complex fibroadenoma were more likely to have other, concomitant high-risk histologic characteristics (e.g., incomplete involution and PDWA). In analyses stratified by involution status and PDWA, complex fibroadenoma was not an independent risk marker for breast cancer. Complex fibroadenoma does not confer increased breast cancer risk beyond other established histologic characteristics.